BBO-11818 not checked
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive assigned dose of BBO-11818 orally (PO)”In the company’s words, NCT06917079 on ClinicalTrials.gov
- Tested for
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C and 6 more
- Main trialPhase 1
- “A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.”In the company’s words, NCT06917079 on ClinicalTrials.gov
Other drugs for Non-Small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up1
- Aug 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Aug 2027 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026